000285005 001__ 285005
000285005 005__ 20240229155059.0
000285005 0247_ $$2doi$$a10.1016/j.xcrm.2023.101249
000285005 0247_ $$2pmid$$apmid:37883975
000285005 0247_ $$2altmetric$$aaltmetric:155773787
000285005 037__ $$aDKFZ-2023-02178
000285005 041__ $$aEnglish
000285005 082__ $$a610
000285005 1001_ $$0P:(DE-HGF)0$$aBlanco-Carmona, Enrique$$b0$$eFirst author
000285005 245__ $$aTumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
000285005 260__ $$aMaryland Heights, MO$$bElsevier$$c2023
000285005 3367_ $$2DRIVER$$aarticle
000285005 3367_ $$2DataCite$$aOutput Types/Journal article
000285005 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1701266327_7708
000285005 3367_ $$2BibTeX$$aARTICLE
000285005 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285005 3367_ $$00$$2EndNote$$aJournal Article
000285005 500__ $$a#EA:B062#LA:B320# / 2023 Nov 21;4(11):101249
000285005 520__ $$aThe isocitrate dehydrogenase (IDH) gene is recurrently mutated in adult diffuse gliomas. IDH-mutant gliomas are categorized into oligodendrogliomas and astrocytomas, each with unique pathological features. Here, we use single-nucleus RNA and ATAC sequencing to compare the molecular heterogeneity of these glioma subtypes. In addition to astrocyte-like, oligodendrocyte progenitor-like, and cycling tumor subpopulations, a tumor population enriched for ribosomal genes and translation elongation factors is primarily present in oligodendrogliomas. Longitudinal analysis of astrocytomas indicates that the proportion of tumor subpopulations remains stable in recurrent tumors. Analysis of tumor-associated microglia/macrophages (TAMs) reveals significant differences between oligodendrogliomas, with astrocytomas harboring inflammatory TAMs expressing phosphorylated STAT1, as confirmed by immunohistochemistry. Furthermore, inferred receptor-ligand interactions between tumor subpopulations and TAMs may contribute to TAM state diversity. Overall, our study sheds light on distinct tumor populations, TAM heterogeneity, TAM-tumor interactions in IDH-mutant glioma subtypes, and the relative stability of tumor subpopulations in recurrent astrocytomas.
000285005 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000285005 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285005 650_7 $$2Other$$aIDH mutation
000285005 650_7 $$2Other$$aastrocytoma
000285005 650_7 $$2Other$$abone-marrow-derived macrophages
000285005 650_7 $$2Other$$aglioma
000285005 650_7 $$2Other$$amicroglia
000285005 650_7 $$2Other$$aoligodendroglioma
000285005 650_7 $$2Other$$arecurrent glioma
000285005 650_7 $$2Other$$asnATAC-seq
000285005 650_7 $$2Other$$asnRNA-seq
000285005 650_7 $$2Other$$atumor microenvironment
000285005 7001_ $$aNarayanan, Ashwin$$b1
000285005 7001_ $$aHernandez, Inmaculada$$b2
000285005 7001_ $$aNieto, Juan C$$b3
000285005 7001_ $$aElosua-Bayes, Marc$$b4
000285005 7001_ $$0P:(DE-He78)1aaab73f118f58d5448020b6034d607a$$aSun, Xueyuan$$b5$$udkfz
000285005 7001_ $$0P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5$$aSchmidt, Claudia$$b6$$udkfz
000285005 7001_ $$aPamir, Necmettin$$b7
000285005 7001_ $$aÖzduman, Koray$$b8
000285005 7001_ $$aHerold-Mende, Christel$$b9
000285005 7001_ $$aPagani, Francesca$$b10
000285005 7001_ $$aCominelli, Manuela$$b11
000285005 7001_ $$0P:(DE-He78)b7bbfa7c998d298484f881999928daa4$$aTaranda, Julian$$b12$$udkfz
000285005 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b13$$udkfz
000285005 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b14$$udkfz
000285005 7001_ $$aPoliani, Pietro Luigi$$b15
000285005 7001_ $$aRehli, Michael$$b16
000285005 7001_ $$aSchlesner, Matthias$$b17
000285005 7001_ $$aHeyn, Holger$$b18
000285005 7001_ $$0P:(DE-He78)7f4df6a9e19a7687f718e557ec4a9a6b$$aTurcan, Sevin$$b19$$eLast author$$udkfz
000285005 773__ $$0PERI:(DE-600)3019420-9$$a10.1016/j.xcrm.2023.101249$$gp. 101249 -$$n11$$p101249$$tCell reports / Medicine$$v4$$x2666-3791$$y2023
000285005 909CO $$ooai:inrepo02.dkfz.de:285005$$pVDB
000285005 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000285005 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1aaab73f118f58d5448020b6034d607a$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000285005 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000285005 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b7bbfa7c998d298484f881999928daa4$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000285005 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000285005 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000285005 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7f4df6a9e19a7687f718e557ec4a9a6b$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000285005 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000285005 9141_ $$y2023
000285005 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL REP MED : 2022$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:51:29Z
000285005 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:51:29Z
000285005 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:51:29Z
000285005 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCELL REP MED : 2022$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-22
000285005 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-22
000285005 9202_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000285005 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000285005 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000285005 9201_ $$0I:(DE-He78)W210-20160331$$kW210$$lLichtmikroskopie$$x2
000285005 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x3
000285005 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x4
000285005 9200_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000285005 980__ $$ajournal
000285005 980__ $$aVDB
000285005 980__ $$aI:(DE-He78)B062-20160331
000285005 980__ $$aI:(DE-He78)HD01-20160331
000285005 980__ $$aI:(DE-He78)W210-20160331
000285005 980__ $$aI:(DE-He78)B320-20160331
000285005 980__ $$aI:(DE-He78)B300-20160331
000285005 980__ $$aUNRESTRICTED